Skip to main content

Table 4 Latest results of studies of emerging therapies

From: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Treatment (reference) N Line ORR (%) mPFS (months) mOS (months)
Poziotinib [56] 115 ≥2 14.8 4.2 NA
Mobocertinib [57] 114 ≥2 28 7.2 24
Amivantamab [58] 81 ≥2 40 8.3 22.8
CLN-081 [59] 42 ≥2 31 NA NA
DZD9008 [60] 56 ≥2 37.5 NA NA
Furmonertinib [61] 10 ≥2 60 NA NA